What is glofitamab?
Glofitamab-gxbm is an immunotherapy treatment that may be used to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy. Glofitamab-gxbm is approved under the name Columvi.
Large B-cell lymphoma is an aggressive type of non-Hodgkin’s lymphoma (NHL) resulting from the malignant proliferation of B cells during their various stages of development. LBCL is one of the most prevalent types of blood cancer among adults.
Glofitamab-gxbm represents a much needed further treatment option for B-cell lymphoma patients and its approval was based on impressive results including a 56% overall response rate and a complete response rate of 43%. 68.5% of patients experienced a long-lasting response of 9 months or longer (median duration of response, 18.4 months).
Columvi belongs to a new class of medicines known as CD20×CD3 T-cell engaging bispecific monoclonal antibodies. It was granted accelerated approval by the FDA on June 15, 2023.
References
- Shirley M. (2023). Glofitamab: First Approval. Drugs, 1–7. Advance online publication. https://doi.org/10.1007/s40265-023-01894-5
- Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Antonio Pinto, Francesc Bosch, Christopher P. Fox, Armando López-Guillermo, Claudia Carlucci, Chun Wu, Kathryn Humphrey, Pauline Baumlin, Martin Barrett, Naseer Qayum, Franck Morschhauser; Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study. Blood 2022; 140 (Supplement 1): 1775–1777. doi: https://doi.org/10.1182/blood-2022-157732
- Wang, C., Liu, Y. Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting. J Hematol Oncol 16, 20 (2023). https://doi.org/10.1186/s13045-023-01420-w
- Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wróbel, T., Offner, F., Trněný, M., Wu, S. J., Cartron, G., Hertzberg, M., Sureda, A., Perez-Callejo, D., Lundberg, L., Relf, J., Dixon, M., Clark, E., Humphrey, K., … Hutchings, M. (2022). Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The New England journal of medicine, 387(24), 2220–2231. https://doi.org/10.1056/NEJMoa2206913
See also:
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
Rybelsus
Rybelsus tablets are used to improve blood sugar control in adults with type 2 diabetes, and may ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Zepbound
Zepbound (tirzepatide) is an FDA-approved weekly injection for weight loss and obstructive sleep ...
Victoza
Victoza helps control blood sugar levels and reduce the risk of serious heart problems in people ...
Saxenda
Saxenda (liraglutide) injection is used for weight loss in obese or overweight patients. Includes ...
Alli
alli blocks the absorption of some of the fat that you eat and is used to treat obesity. Learn ...
Methamphetamine
Methamphetamine is used to treat attention deficit hyperactivity disorder (ADHD) and obesity. Learn ...
Amphetamine
Amphetamine is a stimulant and is used to trat narcolepsy and attention deficit disorder. Includes ...
Phentermine
Phentermine is an appetite suppressant used together with diet and exercise to treat obesity. Learn ...
Related medical questions
- What is the cost of Kymriah?
- Is Adcetris a chemotherapy drug?
- What is the success rate of Epkinly?
- What is the survival rate of Kymriah?
- What is the success rate of Breyanzi?
Related support groups
- B Cell Lymphoma (6 questions, 3 members)